ES2087165T3 - Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion. - Google Patents

Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion.

Info

Publication number
ES2087165T3
ES2087165T3 ES90917506T ES90917506T ES2087165T3 ES 2087165 T3 ES2087165 T3 ES 2087165T3 ES 90917506 T ES90917506 T ES 90917506T ES 90917506 T ES90917506 T ES 90917506T ES 2087165 T3 ES2087165 T3 ES 2087165T3
Authority
ES
Spain
Prior art keywords
pct
treatment
fatty acids
long chain
chain fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917506T
Other languages
English (en)
Inventor
Keith Coupland
Nigel Alan Langley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Croda International PLC
Original Assignee
Croda International PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898927109A external-priority patent/GB8927109D0/en
Priority claimed from GB909016660A external-priority patent/GB9016660D0/en
Application filed by Croda International PLC filed Critical Croda International PLC
Application granted granted Critical
Publication of ES2087165T3 publication Critical patent/ES2087165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)

Abstract

COMPUESTOS QUE CONTIENEN ACIDO NERVONICO (ACIDO CIS-TETRACOS-15 -ENOICO) EN UNA FORMA FISIOLOGICAMENTE ACEPTABLE QUE SON UTILES EN EL TRATAMIENTO DE DESAJUSTES SEMIELINADORES, COMO POR EJEMPLO ESCLEROSIS MULTIPLE. SE PUEDEN AÑADIR A DICHOS COMPUESTOS ACIDOS GRASOS DE CADENA LARGA ADICIONALES CON UNA LONGITUD DE CADENA DE C SUB 16 A C SUB 26, ESPECIALMENTE ACIDO ERUCICO Y SUS ESTERES.
ES90917506T 1989-11-30 1990-11-30 Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion. Expired - Lifetime ES2087165T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927109A GB8927109D0 (en) 1989-11-30 1989-11-30 Pharmaceutical compositions
GB909016660A GB9016660D0 (en) 1990-07-30 1990-07-30 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2087165T3 true ES2087165T3 (es) 1996-07-16

Family

ID=26296282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917506T Expired - Lifetime ES2087165T3 (es) 1989-11-30 1990-11-30 Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion.

Country Status (10)

Country Link
US (1) US5194448A (es)
EP (1) EP0455783B1 (es)
JP (1) JPH07500566A (es)
AT (1) ATE135208T1 (es)
DE (1) DE69025922T2 (es)
DK (1) DK0455783T3 (es)
ES (1) ES2087165T3 (es)
GR (1) GR3019315T3 (es)
NO (1) NO912943L (es)
WO (1) WO1991007955A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
GB9416846D0 (en) * 1994-08-19 1994-10-12 Croda Int Plc Lipid supplementation
GB9418420D0 (en) * 1994-09-13 1994-11-02 Mckeown Neil A Composition for the treatment of an energy imbalance in ruminents
IL119661A0 (en) * 1996-11-20 1997-02-18 Yehuda Shlomo Medical use of composition comprising fatty acids
DE19711777A1 (de) * 1997-03-21 1998-09-24 K D Pharma Gmbh Bestandteil eines Hautpflegemittels
US6652866B1 (en) * 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
US6126986A (en) * 1999-02-23 2000-10-03 Westway Trading Corporation Process for formulating a liquid animal feed ingredient containing sugar and neutralized carboxylic acid
GB9927629D0 (en) 1999-11-24 2000-01-19 Croda Int Plc Compounds
GB0112324D0 (en) * 2001-05-21 2001-07-11 Croda Int Plc Compounds
DE10148065A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft (Ester)-Lysolecithine in Liposomen
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
EP2005189B1 (en) * 2006-03-24 2010-12-29 Metanomics GmbH MEANS AND METHOD FOR DIAGNOSING DIABETES type II
WO2008061334A1 (en) 2006-11-21 2008-05-29 National Research Council Of Canada Lunaria annua, cardamine graeca and teesdalia nudicaulis fae genes and their use in producing nervonic and eicosenoic acids in seed oils
EP3536317A1 (en) * 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
WO2012148927A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
DK2701697T3 (da) 2011-04-26 2020-06-29 Retrotope Inc Oxidative nethindesygdomme
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
EP2780316B1 (en) * 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
CN108698987B (zh) 2015-11-23 2021-07-13 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
CN105853996A (zh) * 2016-03-31 2016-08-17 山东健科生物技术有限公司 一种脑神经激活修复液
CN107441130A (zh) * 2017-08-04 2017-12-08 杨宇明 一种含蒜头果有效提取物的抗阿尔茨海默病的组合物及其应用
NO20181574A1 (en) * 2018-12-06 2020-06-08 Epax Norway As Very long chain fatty acids
US20220233488A1 (en) * 2019-05-31 2022-07-28 Epax Norway As Very long chain fatty acids for treatment and alleviation of diseases
WO2021062383A1 (en) * 2019-09-27 2021-04-01 University Of Virginia Patent Foundation Compositions and methods for preventing and/or reducing weight gain and associated conditions
JP2023514711A (ja) 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法
CN111735888B (zh) * 2020-08-14 2020-11-20 宝枫生物科技（北京）有限公司 用于诊断元宝枫籽油中神经酸起效的生物标记物及其应用
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US4505933A (en) * 1982-02-01 1985-03-19 Hoerrmann Wilhelm Fatty aldehydes in the treatment of Multiple Sclerosis
CH679119A5 (es) * 1988-05-13 1991-12-31 Sandoz Ag

Also Published As

Publication number Publication date
EP0455783B1 (en) 1996-03-13
GR3019315T3 (en) 1996-06-30
DK0455783T3 (da) 1996-04-01
NO912943D0 (no) 1991-07-29
ATE135208T1 (de) 1996-03-15
DE69025922D1 (de) 1996-04-18
EP0455783A1 (en) 1991-11-13
DE69025922T2 (de) 1996-10-02
US5194448A (en) 1993-03-16
WO1991007955A1 (en) 1991-06-13
NO912943L (no) 1991-07-29
JPH07500566A (ja) 1995-01-19

Similar Documents

Publication Publication Date Title
ES2087165T3 (es) Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion.
ATE52245T1 (de) (meth)acrylsaeureester und ihre verwendung zur herstellung von dentalmassen.
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
DE69231793D1 (de) Mikrobielle öle und ihre verwendungen
LV12284A (lv) No kudras izdaliti bioaktivi produkti un tos saturosas farmaceitiskas un kosmetiskas kompozicijas
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
FI914409A0 (fi) Kalciumupptagande inhibitorer.
ATE94757T1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
PH25313A (en) Carboxylic acid derivatives, pharmaceutical compositions containing them
PE20000431A1 (es) Peptidos bioactivos y proceso para la produccion de los mismos
NO165804C (no) Veksthormon-frigjoerende peptider og anvendelse derav.
GB8514975D0 (en) Compositions
ATE3870T1 (de) Ungesaettigte polyesterzusammensetzung, ihre herstellung und verwendung.
DE3676640D1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
SE8800990D0 (sv) Skin-regenerating cosmetic compositon and process for preparing same
ATE135912T1 (de) Thienotricyclen zur behandlung von erkrankungen der bronchien
FI914410A0 (fi) Kalciumupptagande inhibitorer.
ATE121626T1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
DE69008762D1 (de) Retinsäureester von l-Cladinos, Verfahren zu deren Herstellung und ihre Verwendung in der Human- oder Veterinärmedizin und in der Kosmetik.
IT1178800B (it) Composizioni farmaceutiche e loro uso come midriatici
ATE73812T1 (de) Thionophosphonsaeureester.
ATE183391T1 (de) Verwendung von zusammensetzungen essentieller fettsäuren
DE69008761D1 (de) Retinsäureester von D-Desosamin, Verfahren zu deren Herstellung und ihre Verwendung in der Human- oder Veterinärmedizin und in der Kosmetik.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0455783

Country of ref document: ES